Trial · NCT05903040
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Headache pain freedom at 2 hours post dose during the first attack | 2 hours post-dose | The percentage of subjects that report no headache pain at 2 hours after drug intake. Pain will be measured on a 4 point Likert scale (0=none, 1=mild, 2=moderate, 3=severe). |
| Primary | Occurrence of treatment-emergent adverse events | 12 weeks | To evaluate the safety and tolerability of Lasmiditan in migraine subjects |
| Secondary | Headache pain freedom at 2 hours post dose across all treated attacks | 2 hours post-dose for all treated attacks | The percentage of subjects that report no headache pain at 2 hours after drug intake across all' treated attacks. Pain will be measured on a 4 point Likert scale (0=none, 1=mild, 2=moderate, 3=severe). |
| Secondary | Headache pain relief at 2 hours post-dose during the first attack | 2 hours post-dose | The percentage of subjects that report mild or none headache pain at 2 hours after drug intake during the first attack. Pain will be measured on a 4 point Likert scale (0=none, 1=mild, 2=moderate, 3=severe). |
| Secondary | Headache pain relief at 2 hours post-dose across all treated attacks | 2 hours post-dose for all treated attacks | The percentage of subjects that report mild or none headache pain at 2 hours after drug intake across all treated attack. Pain will be measured on a 4 point Likert scale (0=none, 1=mild, 2=moderate, 3=severe). |
| Secondary | Ability to function normally at 2 hours post-dose during the first attack | 2 hours post-dose | The percentage of subjects that self-report no functional disability at 2 hours post-dose. Functional disability will be assessed through the Functional Disability Scale (FDS), a four-point scale: normal, mildly impaired, severely impaired, requires daily activities interruption. |
| Secondary | Ability to function normally at 2 hours post-dose across all treated attacks | 2 hours post-dose for all treated attacks | The percentage of subjects that self-report no functional disability at 2 hours post-dose. Functional disability will be assessed through the Functional Disability Scale (FDS), a four-point scale: normal, mildly impaired, severely impaired, requires daily activities interruption. |
| Secondary | Freedom from the most bothersome symptom (MBS) associated with migraine at 2 hours post-dose during the first attack | 2 hours post-dose | The percentage of subjects that report complete MBS resolution at 2 hours after drug intake. MBS will be measured on a 4 point Likert scale (0=none, 1=mild, 2=moderate, 3=severe). |
| Secondary | Headache recurrence for the first-attack | between 2 hours and 24 hours post-dose | Percentage of subjects who became pain free at 2 hours post-dose and report new headache pain within 24 hours post-dose. |
| Secondary | Rescue medications use for the first attack | between 2 hours and 24 hours post dose | Percentage of subjects who take a rescue medication after 2 hour post-dose. Rescue medications will be measured using a binary scale (0=no consumption, 1=consumption) |
| Secondary | Treatment satisfaction | 2 hours post-dose for all treated attacks | Level of patients' self-reported satisfaction which will be measured on a 0-10 visual analogue scale (0=no satisfaction, 10= the highest satisfaction) and Patients Global Impression of Change (0= no changing, 7= a change that makes the difference). |
| Secondary | Self-reported treatment effectiveness | 12 weeks | Level of patients' self-reported treatment effectiveness measured by Migraine Assessment of Current Therapy (migraine ACT) a 4-item questionnaire about treatment effectiveness and daily life repercussions. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05903040/registered